LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRXBiotechnology
-$0.39 today
- Market cap
- $1.30B
- Beta
- 0.71
- P/E (TTM)
- -21.4
- EPS (TTM)
- -$1.39
Volume 0.36M
Average 0.23M
LBRX Property, Plant & Equipment (Net)
Physical long-term assets such as land, buildings, and machinery, net of accumulated depreciation.
LB Pharmaceuticals Inc Common StockNASDAQ: LBRX
Property, Plant & Equipment (Net) · Q1 FY2026 · quarter ended Mar 2026
Property, plant & equipment (net) falls 8.3% from a year ago
Property, plant & equipment (net) stood at $3.63M at the end of Q1 FY2026, down 8.3% from a year earlier and down 2.7% from the prior quarter. Over 3 fiscal years it compounded at +975.5% a year.
Context
- Property, plant & equipment (net) amounted to 0.9% of total assets at the end of Q1 FY2026, down 19.6 pp from a year earlier.
- Property, plant & equipment (net) increased in 2 of the last 3 fiscal years.
What to watch
Whether property, plant & equipment (net) keeps falling in the next quarterly balance sheet after a -8.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Property, Plant & Equipment (Net) history
USD · from the balance sheet
- Latest · FY2025
- 3.73M USD
- Year-over-year change
- -10.2%
- 3-year CAGR
- +975.5%
| Period | Period end | Property, Plant & Equipment (Net) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.73M | -10.2% |
| FY2024 | 2024-12-31 | 4.16M | +17973.9% |
| FY2023 | 2023-12-31 | 23K | +666.7% |
| FY2022 | 2022-12-31 | 3K | — |
Property, Plant & Equipment (Net) vs competitors
How LBRX compares with its peers on the latest reported figures
- LBRX's Mar 2026 property, plant & equipment (net) of $3.63M is the 6th highest of the 10 companies compared; the peer median is $6.23M.
- Its year-over-year change of -8.3% is the 3rd highest of 9, against a peer median of -13.7%.
- Property, plant & equipment (net) amounts to 0.9% of total assets for LBRX, versus a peer median of 1.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $113.42M | -12.8% | +17.2% | 9.8% | |
| Sep 2026 | $85.87M | +60.9% | -3.8% | 4.8% | |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $11.85M | +8.9% | +237.6% | 2.4% |
| Mar 2026 | $6.3M | -14.0% | +57.2% | 2.3% | |
| Mar 2026 | $6.23M | -13.3% | -2.6% | 1.5% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $3.63M | -8.3% | +975.5% | 0.9% |
| Mar 2026 | $580K | -17.7% | +85.6% | 0.2% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $390K | -79.3% | -65.0% | 0.3% |
DFTXDefinium Therapeutics, Inc. | Sep 2026 | $0 | — | — | 0.0% |
| Jun 2026 | $0 | -100.0% | — | 0.0% | |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding LBRX) | $6.23M | -13.7% | +17.2% | 1.5% | |
Competitors are the stored peer set for LBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRX
Intrinsic Alpha fair value
Locked
Current Price
$40.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.